This company listing is no longer active
Elliptic Laboratories Balance Sheet Health
Financial Health criteria checks 6/6
Elliptic Laboratories has a total shareholder equity of NOK314.0M and total debt of NOK9.0M, which brings its debt-to-equity ratio to 2.9%. Its total assets and total liabilities are NOK335.9M and NOK21.9M respectively.
Key information
2.9%
Debt to equity ratio
NOK 9.00m
Debt
| Interest coverage ratio | n/a |
| Cash | NOK 153.95m |
| Equity | NOK 314.01m |
| Total liabilities | NOK 21.90m |
| Total assets | NOK 335.91m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ELABSO's short term assets (NOK204.0M) exceed its short term liabilities (NOK16.3M).
Long Term Liabilities: ELABSO's short term assets (NOK204.0M) exceed its long term liabilities (NOK5.6M).
Debt to Equity History and Analysis
Debt Level: ELABSO has more cash than its total debt.
Reducing Debt: ELABSO's debt to equity ratio has reduced from 36.7% to 2.9% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ELABSO has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ELABSO has sufficient cash runway for 1.6 years if free cash flow continues to grow at historical rates of 7.4% each year.